{
    "clinical_study": {
        "@rank": "26712", 
        "arm_group": {
            "arm_group_label": "Oracea", 
            "arm_group_type": "Experimental", 
            "description": "Oracea (doxycycline USP, 40mg[30mg immediate release/ 10mg delayed release beads] taken once daily in the morning on an empty stomach, one hour before meals or two hours after.\nOral dose for 12 weeks"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to characterize rosacea patients', being treated with Oracea,\n      perception through visual analog scale reporting."
        }, 
        "brief_title": "Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Papulopustular Rosacea", 
        "condition_browse": {
            "mesh_term": "Rosacea"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women\n\n          -  25-70 years\n\n          -  Diagnosis of papulopustular rosacea\n\n          -  Eligible for Oracea treatment\n\n        Exclusion Criteria:\n\n          -  Allergies to components of investigational product and/or hypersensitivity to\n             tetracyclines\n\n          -  Taken systemic therapy directed at improving rosacea, including antibiotics, within\n             30 days prior to baseline visit\n\n          -  Used topical rosacea treatment within 30 days prior to baseline visit\n\n          -  Have active ocular rosacea and/or blepharitis/meibomianitis requiring systemic\n             treatment by an opthalmologist\n\n          -  Previously failed to have improvement of rosacea with appropriate use of systemic\n             tetracycline family of antibiotics\n\n          -  Exposed to intense/excessive ultraviolet (UV) radiation within one week prior to\n             baseline and/or who forsee unprotected and intense/excessive UV exposure during the\n             course of the study\n\n          -  Have planned surgical procedures during the course of the study\n\n          -  Have used tetracycline antibiotics within 30 days prior to baseline visit or during\n             study\n\n          -  At risk in terms of precautions, warnings, and contraindications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01872715", 
            "org_study_id": "GLI.04.SPR.US10233"
        }, 
        "intervention": {
            "arm_group_label": "Oracea", 
            "intervention_name": "Oracea", 
            "intervention_type": "Drug", 
            "other_name": "doxycycline USP, 40 mg (30 mg immediate release/ 10 mg delayed release beads)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Doxycycline", 
                "Doxycycline hyclate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Papulopustular Rosacea", 
            "Oracea", 
            "anti inflammatory doxycycline"
        ], 
        "lastchanged_date": "July 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Carrollton", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75006"
                }, 
                "name": "Stephens & Associates Dallas Research Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Rosacea score on the Visual Analog Scale", 
                "safety_issue": "No", 
                "time_frame": "up to  week 12"
            }, 
            {
                "measure": "Clinician's Erythema Assessment", 
                "safety_issue": "No", 
                "time_frame": "baseline, week 2, week 6, and week 12 (exit)"
            }, 
            {
                "measure": "Investigator Global Assessment of Rosacea scores", 
                "safety_issue": "No", 
                "time_frame": "baseline, week 2, week 6, and week 12 (exit)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01872715"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Patient's Self Assessment of redness", 
                "safety_issue": "No", 
                "time_frame": "baseline, week 2, week 6, and week 12 (exit)"
            }, 
            {
                "measure": "Rosacea-Specific Quality of Life Index", 
                "safety_issue": "No", 
                "time_frame": "baseline, week 2, week 6, and week 12 (exit)"
            }
        ], 
        "source": "Galderma Laboratories, L.P.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galderma Laboratories, L.P.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}